Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in

• click to rate

  Posted by Two Blokes Apr 17 - Filed in Stock - 9 views
  
  Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK , April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligomers that target the KIT gene — a clinically validated oncogene associated with gastrointestinal stromal tumors (GIST), leukemia, mastocytosis, and other cancers.